Russia Transfers Technology for Production of Next-Generation Medicines and Vaccines to Vietnam
A significant step in Vietnam - Russia medical cooperation has been marked by the signing of an agreement on the transfer of technology for the production of modern biopharmaceuticals and vaccines.
On the evening of September 12 in Hanoi, Ms. Đào Hồng Lan - Minister of Health of Vietnam, and Mr. Mikhail Murashko - Minister of Health of Russia, witnessed the signing ceremony of a cooperation agreement between Medsintez Pharmaceutical Company (Russia) and the VNVC Vaccine and Biopharmaceutical Plant (Vietnam).
Many Essential Products to Be Produced in Vietnam
Under the agreement, Medsintez will transfer to Vietnam the technology for mass production of key biopharmaceuticals such as recombinant insulin, albumin, diabetes treatments (liraglutide, semaglutide), anticoagulants (heparin), hormones for infertility treatment, as well as advanced antiviral drugs.
In particular, Triazavirin - a drug used for treating influenza and other viral diseases - will undergo clinical trials in Vietnam for potential application in dengue treatment, a disease currently at high risk of widespread outbreaks in many localities.
Toward the Production of Next-Generation Vaccines
The agreement also paves the way for joint research, clinical trials, and the production of next-generation vaccines. By the end of 2027, the VNVC Vaccine and Biopharmaceutical Plant is expected to release the first batches of vaccines and biopharmaceuticals developed using Russian technology.
Ms. Đào Hồng Lan affirmed: “Healthcare has always been a pillar in the cooperation between Vietnam and the Russian Federation. This technology transfer not only helps us access modern medicines and vaccines but also enhances production capacity, making us more proactive in responding to epidemics.”
Advantages from VNVC’s Network and Medsintez’s Experience
VNVC is currently the largest vaccination system in Vietnam with nearly 240 centers, providing tens of millions of vaccine doses annually. With the new plant in operation, VNVC will be able to produce hundreds of millions of doses of vaccines, serving both domestic and regional needs.
Meanwhile, Medsintez is one of Russia’s leading biotechnology enterprises, with over 20 years of experience in manufacturing specialized pharmaceuticals and internationally certified medical equipment.
A Strategic Step in Vietnam - Russia Relations
This event is regarded as a strategic milestone, not only enhancing Vietnam’s healthcare capacity but also demonstrating the long-standing, reliable cooperation between the two nations.
The technology transfer agreement not only has immediate significance in strengthening epidemic preparedness but also lays the foundation for Vietnam to become more self-reliant in the production of medicines and vaccines. It is considered a strategic move, contributing to the consolidation of comprehensive Vietnam - Russia cooperation, while opening opportunities for Vietnam to emerge as a regional hub for research, production, and supply of high-quality biopharmaceuticals and vaccines in the coming years.
Sources:
- Bao Chinh Phu. (September 13, 2025). Russia transfers technology for the production of modern medicines and vaccines to Vietnam.
- VnExpress. (September 13, 2025). Russia transfers technology for the production of biological medicines to Vietnam.
- Dan Tri. (September 13, 2025). Russia transfers technology for the production of modern medicines and vaccines to Vietnam.
